Clinical Trials Browser

Recruiting × Neoplasm, Residual × Clear all

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

NCT07069595 2026-03-05

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07211178 2026-03-04

GEMINI Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07291921 2026-03-03

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Lung Neoplasms, Neoplasm, Residual

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT07134088 2026-01-29

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT01499394 2026-01-21

Caris Biorepository Research Protocol

100,000 enrolled

Neoplasms, Neoplasm, Residual

NCT07356882 2026-01-21

EURHOLY

Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07280494 2025-12-12

S101MRD

Phase 1 Recruiting

Lymphoma, Neoplasm, Residual

NCT05595408 2025-12-09

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

Phase NA Recruiting

Neoplasm, Residual

NCT04707300 2025-11-20

HTLP-ONCO

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06828991 2025-10-20

GOLD

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT05232916 2025-10-03

FLAMINGO-01

Phase 3 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT01898039 2025-10-02

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Phase 1/2 Recruiting

Melanoma, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06993675 2025-08-29

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06287749 2025-07-10

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Neoplasm, Residual

NCT06287814 2025-07-10

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Neoplasm, Residual

NCT05196087 2025-07-02

NIP IT!

BreastDermatologicEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Breast Neoplasms, Melanoma, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07003737 2025-06-04

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

Phase NA Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06718244 2025-05-23

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06963307 2025-05-09

LumenDx

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05959720 2025-05-07

BRALLA

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05198154 2025-04-23

CR1STAL

Neoplasm, Residual

NCT06930807 2025-04-16

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06111105 2025-03-30

GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Colorectal Cancer

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT06875609 2025-03-26

ctDNA in Cutaneous Squamous Cell Carcinoma

Skin Neoplasms, Neoplasm, Residual

NCT04768426 2025-03-20

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06885476 2025-03-20

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06886074 2025-03-20

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04841148 2025-03-11

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT06230185 2025-01-07

B-STRONGER-I

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms